Literature DB >> 12144898

Therapeutic vaccination against chronic viral infections.

Pierre Vandepapelière1.   

Abstract

Chronic viral infections such as those caused by hepatitis B virus, human papilloma virus, herpes simplex virus, and HIV, in theory, present logical targets of active specific immunotherapy. Indeed, immunological mechanisms are involved in several aspects of their pathogenesis and natural course, such as virus persistence, destruction of infected cells and control of viral replication. Therapeutic vaccination could therefore be an adequate replacement for, or adjunct to, existing therapies. Almost all approaches to therapeutic vaccination have been evaluated in those four disease areas. Despite encouraging results in animals none of these attempts has, so far, been completely successful in the human setting. However, with a better understanding of the immunological mechanisms involved in the control of disease successful therapeutic vaccines, used alone or in combination with other therapies, are an achievable goal.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12144898     DOI: 10.1016/s1473-3099(02)00289-x

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  3 in total

1.  Topical treatment with nerve growth factor in an animal model of herpetic keratitis.

Authors:  Alessandro Lambiase; Marco Coassin; Nicola Costa; Paolo Lauretti; Alessandra Micera; Emiliano Ghinelli; Luigi Aloe; Paolo Rama; Stefano Bonini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-05-04       Impact factor: 3.117

2.  Enhancement of humoral and cellular immunity with an anti-glucocorticoid-induced tumour necrosis factor receptor monoclonal antibody.

Authors:  Jose F Ponte; Paul Ponath; Reema Gulati; Michael Slavonic; Michael Paglia; Adam O'Shea; Masahide Tone; Herman Waldmann; Louis Vaickus; Michael Rosenzweig
Journal:  Immunology       Date:  2010-02-26       Impact factor: 7.397

3.  Vaccines: past, present and future.

Authors:  Stanley A Plotkin
Journal:  Nat Med       Date:  2005-04       Impact factor: 53.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.